



**CIRCULAR NO.: H.36.../2021**

**TO: THE CHIEF OF OPERATIONS  
CHIEF DIRECTORS / DIRECTORS / DISTRICT MANAGERS  
HEADS: HOSPITALS, COMMUNITY HEALTH CENTRES, CLINICS  
EXECUTIVE DIRECTOR HEALTH: CITY OF CAPE TOWN**

**N.B. FOR CIRCULATION TO ALL MEDICAL, PARAMEDICAL, PHARMACEUTICAL AND NURSING STAFF**

**ERRATA TO THE PRIMARY HEALTH CARE STANDARD TREATMENT GUIDELINES AND ESSENTIAL MEDICINES LIST, 2020, 7TH EDITION and ADULT HOSPITAL LEVEL STANDARD TREATMENT GUIDELINES AND ESSENTIAL MEDICINES LIST, 2019, 5TH EDITION**

Healthcare professionals are referred to the attached notice, Reference: 2021/02/25/EDP/01: **Errata to the Primary Health Care Standard Treatment Guidelines and Essential Medicines List, 2020, 7th Edition and Adult Hospital Level Standard Treatment Guidelines and Essential Medicines List, 2019; 5th Edition**, issued by the National Department of Health on 09 March 2021.

Please note the following corrections to the Primary Health Care (PHC) 2020, 7th edition and Adult Hospital Level, 2019, 5th edition Standard Treatment Guidelines (STGs) and Essential Medicines List (EML):

**1. Lamivudine dose: 300 mg**

- PHC - Section 21.3.6.1: Post exposure prophylaxis, occupational; page 21.50.
- Adult Hospital Level - Section 10.5.1: Post-exposure prophylaxis, occupational; page 10.30.

**2. PEP for healthcare worker following occupational HIV exposure**

- Adult Hospital Level - Section 10.5.1: Post-exposure prophylaxis, occupational; page 10.31.

**Please update your STG and EML reference material to reflect the above amendments.**

**MS K LOWENHERZ**

**DIRECTOR: PHARMACY SERVICES**

**DATE: 12/03/21**

4th Floor, 16 Chiappini Street, Cape Town, 8001

Tel: +27 21 483 6198 / +27 21 483 8702

Email: Yasmina.Johnson@westerncape.gov.za

P O Box 2060, Cape Town, 8000

[www.westerncape.gov.za](http://www.westerncape.gov.za)



**ERRATA TO THE PRIMARY HEALTH CARE STANDARD TREATMENT GUIDELINES AND ESSENTIAL MEDICINE LIST, 2020, 7<sup>TH</sup> EDITION and ADULT HOSPITAL LEVEL STANDARD TREATMENT GUIDELINES AND ESSENTIAL MEDICINE LIST, 2019, 5<sup>TH</sup> EDITION**

Please note the following corrections to the Primary Health Care (PHC) 2020, 7<sup>th</sup> edition and Adult Hospital Level, 2019, 5<sup>th</sup> edition Standard Treatment Guidelines (STGs) and Essential Medicine List (EML):

**a) Lamivudine dose: 300 mg**

- PHC - Section 21.3.6.1: Post exposure prophylaxis, occupational; page 21.50.
- Adult Hospital Level - Section 10.5.1: Post-exposure prophylaxis, occupational; page 10.30

For the indications listed above, the dose for lamivudine, as part of a dolutegravir-containing fixed dose combination preparation, corrected to 300 mg, as follows:

|  |  |
|--|--|
| <b>When PEP is indicated:</b>  |  |
| • Tenofovir, oral, 300 mg daily for 4 weeks (provided baseline eGFR is >50 mL/minute). |  |
| and  |  |
| • Lamivudine, oral, <del>200</del> 300 mg daily for 4 weeks                            |  |
| and  |  |
| • Dolutegravir, oral 50 mg once daily for 4 weeks.                                     |  |
| <b>In WOCP, pregnant women &lt;6 weeks gestation, or where DTG is not tolerated:</b>   |  |
| • Tenofovir, oral, 300 mg daily for 4 weeks (provided baseline eGFR is >50 mL/minute). |  |
| and  |  |
| • Emtricitabine, oral, 200 mg daily for 4 weeks.                                       |  |
| and  |  |
| • Atazanavir/ritonavir 300/100 mg daily for 4 weeks.                                   |  |
| Or   |  |
| • Lopinavir/ritonavir 200/50 mg, oral, 2 tablets 12 hourly for 4 weeks.                |  |

**b) PEP for healthcare worker following occupational HIV exposure**

- Adult Hospital Level - Section 10.5.1: Post-exposure prophylaxis, occupational; page 10.31

The table describing PEP for healthcare worker following occupational HIV exposure, updated as follows:

| Exposure   | HIV Status of source patient |  |
|--|------------------------------|--|
|  | Negative                     | Unknown or positive  |
| Intact skin  | No PEP                       | No PEP   |
| Mucosal splash<br>or<br>non-intact skin<br>or<br>percutaneous injury | No PEP                       | <b>PEP</b><br>• TDF+3TC+DTG<br><b>OR (in WOCP/ DTG not tolerated)</b><br>• 3-drug regimen (PI-based) |

Provinces and Health Care Facilities are requested to distribute and communicate this information.

Comments may be submitted via e-mail or post to:

Essential Drugs Programme


Private Bag X828

**PRETORIA**

0001

E-mail: [SAEDP@health.gov.za](mailto:SAEDP@health.gov.za)

Kind regards



**MS K JAMALOODIEN**  
**DIRECTOR: AFFORDABLE MEDICINES**  
**DATE: 9 March 2021**